0,uptake
1,subunits
2,reoperation for bleeding
3,reduced cardiac diameters
4,end-tidal
5,carvedilol
6,regulator
7,left ventricular diastolic
8,involving
9,studies per outcome
10,hazard ratio
11,clinical trials
12,egfr
13,centers
14,reverses
15,non-linear
16,rvpo
17,effectiveness
18,undergo
19,flow pump
20,right ventricular contractile function
21,madit-crt
22,ctnt
23,normal albumin concentration
24,hospital mortality
25,echocardiograms
26,hospitalized for heart failure
27,regression
28,channelopathies
29,intermediate
30,irs2
31,underlying mechanism
32,evidenced
33,right-sided
34,identifies
35,acute care
36,multisystem
37,decreased mortality
38,statistics
39,all-cause medical hospitalization
40,antihyperglycemic
41,reduced risk
42,normal geometry
43,compensatory hypertrophy
44,major concerns
45,cause of death
46,reduce
47,community
48,three
49,steadily
50,myofibre
51,induced
52,inhibition of protein kinase
53,idiopathic
54,myocardial function
55,curve
56,adult
57,humanized
58,obstructed
59,downregulated
60,surgical ring
61,receptor blockers
62,underwent transcatheter
63,reduced mortality
64,central pattern
65,myocyte diameter
66,post-acute
67,flow
68,antiarrhythmic
69,primary safety end
70,ffm
71,hf-related
72,tunel
73,de novo
74,clinical deterioration
75,median rate
76,log-rank
77,endothelial growth factor
78,association
79,anemia
80,knockdown
81,non-urbanized
82,postnatal mammalian
83,antiadrenergic
84,transcription factor
85,contrast agent
86,cardiac death
87,nonpublic
88,decompensated
89,driving
90,swine
91,follow-up tests
92,net-reclassification-improvement
93,changes in
94,social
95,failing fontan
96,lability
97,affects
98,responsible for increased sv
99,abrogate
100,iron
101,relation
102,inhibition on hemodynamic
103,transthoracic echocardiography
104,extended
105,developmental chromatin
106,descriptive
107,annual ed
108,inducing hyperkalemia
109,investigate
110,perceived
111,deranged
112,described
113,definitions
114,signaling pathway
115,largely
116,transfusion protocols
117,right ventricular contractile reserve
118,annuloplasty
119,drawn
120,12-s
121,subunit
122,filling
123,arrhythmia-related
124,destination therapy
125,non-ischemic heart failure samples
126,cs
127,proof-of-principle
128,exercise
129,exertional
130,excised
131,venous
132,tests
133,e'lateral
134,bromodomain proteins
135,abnormal hr
136,wasting
137,subcellular alterations
138,activated
139,infarcted
140,sudden death
141,early-activated
142,sudden
143,hno
144,motion
145,norepinephrine-induced
146,expenditures
147,medication regimen
148,sub-sample
149,heart failure
150,inhibition
151,performers
152,all-cause hospitalisations
153,overlapped
154,median stay
155,setting and participants
156,atrial structure
157,real-world
158,high-frequency
159,denervation
160,over tissue
161,sample
162,safe
163,regulating
164,discharged
165,natural
166,clinical diastolic dysfunction
167,hypokalemia
168,u.s.
169,congenital lesions
170,pressures
171,left ventricular midpapillary level
172,reviewers
173,independent of age
174,alleviate
175,advanced management
176,following
177,statistical model
178,controlled trial
179,nonstandardized
180,exerts
181,post-dash
182,large-scale
183,normalizing
184,depressed
185,lb
186,filling formalism
187,all-cause mortality
188,longitudinal change
189,challenging
190,deals
191,arrhythmias
192,alive
193,blood pressure
194,revealed
195,vs. hospital
196,2-vessel
197,moderate
198,communication
199,assessed
200,publicly
201,tolvaptan
202,long-term mortality
203,public health problem
204,crossover
205,infusion
206,decoy
207,norepinephrine
208,edge-to-edge
209,occurring
210,insurance
211,opening
212,basal contractility
213,cad
214,american college of cardiology
215,group of patients receiving
216,trials
217,derangement
218,deaths
219,limited mortality
220,reassessed
221,breakdown
222,single-cohort
223,small-molecule
224,pro-adrenomedullin
225,unknown
226,responsiveness
227,opposed
228,m2
229,clinical composite response
230,free-breathing
231,measuring hospital
232,combined aerobic
233,clinical data reviewed
234,treated
235,high-cost
236,left-to-right
237,used
238,study-related
239,throughput
240,alleviating
241,separate
242,clinical outcomes
243,outcome-monitoring
244,left bundle
245,wall thickness
246,benefits
247,p38
248,social support score
249,emergency cardiac catheterization
250,withdrawal of sympathetic tone
251,changes in treatment
252,collected
253,hdl-mediated
254,post-myocardial
255,exclude
256,tolerated
257,inflammatory markers
258,2-erk1
259,clinical and radiological signs
260,qualitative study
261,overlapping
262,penalties
263,endothelial function
264,subscales
265,conjunction
266,persistent af
267,fixed-rate
268,ms
269,antirheumatic
270,systemic / uv treatment
271,oxygenation membrane
272,computed
273,new-onset
274,branch block
275,protective mechanisms
276,surgical indications
277,s'lateral
278,department of cardiology
279,obese zsf1
280,young woman
281,anaerobic
282,spironolactone
283,reversible myocardial ischemia
284,decreased stroke
285,sequence
286,revascularization
287,sodium
288,quality-of-life score
289,conjoint education
290,enos-ser
291,attributable
292,restoring
293,adjusting
294,diabetes mellitus
295,immunohistochemistry
296,end-stage
297,link
298,with no use
299,3m
300,post-aac
301,conduction
302,operations
303,commoner
304,use of devices
305,americans
306,progressive
307,health outcomes
308,individualized
309,control adenovirus
310,five
311,6mwt
312,underwent catheterization
313,northwest united states
314,abnormal liver
315,systemic blood pressure
316,rest
317,trans
318,pathobiology
319,chemotherapy
320,encouraging
321,admissions
322,after
323,growth factor blockade
324,contextual factors
325,limitation
326,stress markers
327,btt
328,control
329,placebo-treated
330,cost per patient
331,collect
332,cardiac sodium
333,sudden cardiac death
334,ejection fraction
335,composite
336,biomedical
337,fistula
338,at
339,c=24.3
340,new-user
341,europe
342,breast
343,trial
344,long-term
345,endpoint
346,inhibition halts
347,indeterminable
348,substudy
349,young
350,infarcted hearts
351,human-to-human
352,multivariate
353,atrial natriuretic peptide
354,formed
355,tissue samples
356,cost
357,chelation regimens
358,myofiber
359,combination
360,conducted
361,x12
362,lc-ms
363,recreational athletes
364,two
365,constants
366,clinical benefit
367,change in distribution
368,competing risk
369,transduction
370,evidence shows
371,ethically
372,rehabilitation
373,specialty hospital
374,settings
375,precipitating factor
376,abrogated
377,standard
378,transcatheter
379,ablation
380,time span
381,followed
382,pharmacological armamentarium
383,networks
384,cpr
385,overstimulation
386,co-morbidities
387,physical
388,canada
389,enrichment analysis
390,control group
391,blockade
392,pioglitazone
393,lean body
394,subclinical
395,be
396,emergency department
397,15-ml
398,survival
399,internal
400,combining salt loading
401,investigation
402,hh
403,sequential phosphorylation
404,frame
405,suppresses
406,following ring
407,hretn
408,overexpression
409,time-dependent
410,underlying
411,concomitant
412,coexist
413,context
414,depresses
415,downward
416,differentiation
417,setting
418,reactivate
419,organizations
420,nine pigs
421,compute odds
422,receptor blockade
423,longitudinal study
424,beta-blockers
425,log2 ng
426,nuts
427,sitagliptin
428,obstructive
429,unloading
430,alendronate
431,midregional proanp
432,center 's experience
433,hdl
434,endopeptidase
435,athletes
436,tracked
437,icu
438,conscious
439,pulseless ventricular fibrillation
440,single -
441,recent findings
442,left ventricular ejection time
443,preceding mechanisms
444,read
445,exacerbated
446,obstructive pulmonary disease
447,independent predictor
448,outline
449,east
450,feasible
451,us
452,left ventricular dysfunction
453,cyclic
454,trainings
455,assessment of cardiac function
456,cohort
457,obtained
458,lvet
459,develop treatments
460,mediated
461,eligibility
462,defibrillator
463,combined
464,atropine
465,lvef
466,nonidentification
467,reference lists
468,infarcted rats
469,community-based
470,followed-up
471,research
472,assembly
473,transverse
474,ivabradine-treated
475,sport
476,impairment
477,health-care budget
478,cardiac-resynchronization therapy
479,cachexia
480,underwent heart transplant
481,cardiopulmonary
482,respectively
483,effective arterial elastance
484,yield
485,occluded
486,peripheral oedema
487,diastole
488,permeability
489,asymptomatic
490,utility
491,clinical studies
492,bridging
493,dilatation
494,principal
495,event-free rate
496,contextual framework
497,high-quality
498,widespread
499,decongestion
500,perturbed
501,bisphosphonates
502,attendance
503,systole
504,left anterior
505,test
506,depolarization
507,debilitating stroke
508,guideline
509,unintentional
510,nontreatment
511,muscle strip
512,ss20
513,randomised-controlled
514,opposing
515,extracted
516,composite of death
517,treadmill
518,safety monitoring board
519,aerobic capacity
520,tac
521,iron-deficient
522,e'septal
523,burden
524,re-express
525,self-rated
526,before the surgery
527,research design
528,modality
529,prediction rule
530,blood loss
531,np
532,two-center
533,considerations
534,peripheral
535,critical
536,volunteers--a
537,lesion
538,slope
539,forty-six
540,refractory
541,medical records
542,elevated
543,confirm
544,clinicians
545,nonsignificant
546,surveys
547,accessory
548,cross-linking
549,women 's health initiative
550,multivariable adjustment
551,histone
552,eo-cfus
553,obese
554,repression
555,hospitals
556,biological phenotype
557,valve
558,matched
559,composite quality
560,pre-post
561,deficits
562,nonpace
563,aor
564,pg
565,optimal treatment
566,exertion
567,confer
568,mechanical circulatory
569,mediate
570,myocardial fibrosis
571,diet
572,non-hf
573,interpretation
574,pharmacological treatment
575,poorly
576,transferred
577,non-aa
578,income
579,latin america
580,non-biological
581,chelation
582,mirnas
583,unfavourable
584,on
585,induction
586,ras
587,haematopoietic
588,endothelin
589,review
590,doxorubicin
591,right ventricle
592,cost-minimization
593,complexities
594,liver
595,patients
596,inhibitor
597,activators
598,ischemic
599,readmission metrics
600,without
601,high-risk
602,deferred
603,coagulability
604,oxygen
605,bioenergetics
606,coronary artery occlusion
607,observational study
608,resonance
609,cardiac magnetic resonance imaging
610,stable heart failure
611,camp
612,biosynthetic enzymes
613,at-risk
614,individual scales
615,surrogates
616,co-primary
617,attenuates
618,rhythm-control
619,treating patients
620,hazard ratios
621,right ventricular pacing
622,relaxation
623,receiver
624,human failing hearts
625,growth factor-β
626,on the same day
627,post hoc
628,temporary right ventricular
629,empirically
630,life
631,apical rotation
632,anti-neoplastic
633,rationale
634,twofold
635,from the pressure
636,mutant mice
637,diastolic dysfunction
638,triangular resection
639,longitudinal systolic strain
640,vitro showed
641,race
642,surgically
643,subproteomes
644,structured
645,without cardiotoxicity
646,short-term treatment
647,communicate
648,examined
649,adjusted
650,stay
651,postoperative mortality
652,p38alpha
653,per capita
654,sympathetic
655,renin-angiotensin-aldosteron
656,with ventricular
657,tachy
658,deficiency
659,all settings
660,impaired
661,open stent
662,recommendation
663,rr
664,myocardial extracellular matrix
665,pde2
666,ste
667,movement
668,left ventricular dilatation
669,uncertainty
670,between
671,result
672,inhibitors
673,reduces
674,mice
675,cardioverter-defibrillators
676,ivabradine
677,overload
678,myocardial tissue
679,echo-doppler
680,centrifugal-flow
681,tachycardia
682,mortality
683,ch
684,acute care hospitals
685,confounders
686,anesthetized
687,exacerbates
688,elicited
689,serum resistin
690,financial burden
691,end diameter
692,acute heart failure trials
693,ventricular
694,organ failure
695,all-cause hospitalization
696,standard practice
697,pb
698,influence
699,data
700,surrogate
701,adjustment for age
702,cpg
703,reported
704,m7
705,on the primary endpoint
706,indicated
707,sensitized
708,myoctyes
709,right ventricular dysfunction
710,change scores
711,va-rt
712,alternative
713,clcnka
714,failing heart
715,multivariate-adjusted
716,absorptiometry
717,series
718,turnaround
719,atrial explants
720,peripheral muscle pump
721,misdiagnosis
722,modern society
723,severe hyperkalemia
724,antiarrhythmic drugs
725,confidence interval
726,stem cell
727,national
728,sub-groups
729,signaling pathways
730,add-on
731,lower killip
732,myocardial ischemic
733,measured
734,central end-systolic
735,participant
736,adaptive
737,practice settings
738,age groups
739,care management
740,renal dnx
741,steady
742,up-regulated
743,percutaneous coronary
744,compliance
745,clear organic
746,detectable
747,functional capacity
748,healthcare
749,left ventricular assist
750,self-management
751,embolism
752,class i
753,energy substrate
754,ischemic conditioning
755,rate-control
756,linked
757,exogenous
758,publications
759,calreticulin
760,angiography
761,adenosine
762,"community of 150,000 population"
763,underwent testing
764,avp
765,congestion
766,tobacco
767,β1-adrenergic
768,overwhelming
769,rehospitalization
770,viable
771,risk-standardized mortality
772,prespecified
773,stem cell-derived
774,heart rate
775,ranging
776,404.x1
777,beginning
778,clinical trials-enriching
779,wave
780,training-induced
781,main effect
782,under
783,estimated
784,left ventricular
785,bradycardic
786,long-term support
787,unilateral renal dnx
788,serum cystatin
789,energy transfer-based
790,normal cardiac function
791,major branches
792,procedures
793,atherosclerotic
794,hemoglobin
795,statistic
796,upregulated
797,lowest
798,insulin-resistance
799,administration
800,density
801,shortcomings
802,reversal of detrimental alterations
803,assist
804,methotrexate
805,rabbits
806,co
807,pf
808,confidence level
809,practice-level
810,functional efficacy
811,reclassified
812,bundle-branch block
813,tobacco use
814,time-varying
815,case-fatality rate
816,phenylephrine
817,died
818,background
819,annular plane systolic excursion
820,benefit
821,with severe pulmonary hypertension
822,aac
823,actin cytoskeleton pathways
824,systolic hf
825,in-hospital
826,childhood
827,investigated
828,care clinicians
829,out-patient
830,facilitate
831,competitive collateral growth patterns
832,dearth
833,contractile function
834,ethnic
835,peptide levels
836,participants
837,functional decline
838,alendronate-
839,improved survival
840,non-invasively
841,comanagement
842,pre-participation
843,etiologic
844,diagnosis
845,chf
846,human embryonic kidney
847,measurement
848,right heart failure
849,620 feet
850,at the time of surgery
851,random-effects
852,primary oscillations
853,readmission reduction program
854,significant improvements
855,undiagnosed
856,explored
857,oxygenation on renal function
858,clinical change
859,inflammation
860,sensitivity
861,interatrial shunt
862,hf-action
863,defibrillators
864,evaluation and management
865,subjects
866,secretion
867,drives
868,dt
869,bridge
870,medium
871,pressure
872,hand-searching
873,tonometric indices
874,lower socioeconomic status
875,glucose
876,meta-analysis
877,transfusions
878,deter
879,health status
880,likelihood
881,improved
882,icd
883,newer drugs
884,pulmonary hypertension
885,care unit
886,blood testing
887,control model
888,nicorandil
889,ng
890,left ventricular function assessment
891,inotropic
892,haemodynamic
893,high-volume
894,qt intervals
895,all-cause hospitalizations
896,post-lvad
897,sulfonylureas
898,unclear
899,drugs
900,thrombosis
901,myocardial ischemia
902,developmental impairment
903,ontario
904,infarct
905,surgical
906,infancy
907,burden of heart failure hospitalizations
908,t1-mapping
909,coated
910,interfere
911,women
912,inotropic effect
913,cardiac magnetic resonance
914,on the above parameters
915,functional assessment
916,susceptibility
917,severe-end-stage
918,conductance
919,looping
920,median bnp
921,operative
922,witness
923,cpcs
924,obstruction
925,activation therapy
926,applicable
927,left ventricular assist system
928,axis
929,exhaustion
930,vegf
931,forward
932,coefficient
933,co-activating
934,activation sequence
935,icds
936,normal
937,protective
938,relieve
939,intolerance
940,myocardial
941,eseptal
942,feeding
943,invasive hemodynamic assessments
944,function
945,distressing
946,air pollution
947,echocardiographic measures
948,abundance
949,investigations
950,study-a multicenter
951,pro-brain-type
952,immunoassays
953,outpatient assessments
954,protocol
955,mr
956,nitric oxide
957,quality-adjusted
958,postoperative echocardiography
959,o2
960,aortic
961,contributed
962,downregulation
963,heart
964,underperfusion
965,intima-media thickness
966,histologically
967,changing
968,serum potassium
969,sickle cell
970,tnf
971,undecided
972,given
973,translating
974,outpatient
975,evaluable
976,annular velocity
977,endothelial
978,normal hearts
979,downward regression line
980,japan
981,confirmed
982,nt-probnp
983,elevated resistin
984,resistin
985,resynchronization
986,discontinuation
987,[ sham-innervated
988,consultation
989,auc
990,joint
991,progenitors
992,refill
993,workload
994,p=0.004
995,apex
996,antihypertensive
997,metoprolol
998,reduced clinic
999,rgk
1000,cri
1001,acute
1002,defibrillator-crt
1003,over conventional clinical
1004,left ventricular systolic dysfunction
1005,mechanism of action
1006,safety
1007,left ventricle
1008,surviving
1009,myofilament
1010,validity
1011,chemotherapy-induced
1012,clinically
1013,cardioverter-defibrillator
1014,therapeutics
1015,staff
1016,angioplasty
1017,stabilize
1018,angiotensin
1019,after the surgery
1020,time-domain
1021,abnormal chamber patterning
1022,analyze
1023,undergoing procedures
1024,hemolysis
1025,reduced
1026,cardiac hypertrophy
1027,stiffness
1028,aforementioned
1029,lower natremia
1030,low-volume
1031,borderline association
1032,erasers
1033,spectrometry
1034,peptide
1035,high-density
1036,lesions
1037,surgical correction
1038,hemodynamic
1039,short-term
1040,consumption
1041,pulmonary vascular resistance
1042,encoding
1043,severe hypertension
1044,protocol-driven
1045,signalling
1046,rule
1047,men
1048,authors
1049,paediatric heart failure
1050,reduced ejection fraction
1051,modest reduction
1052,cfa
1053,xo
1054,ankle-brachial index
1055,thickness
1056,exchanges
1057,congestion-like
1058,e'mean
1059,mutant
1060,cgmp
1061,common emergency department
1062,demographics
1063,abnormal
1064,regurgitation
1065,overexpress
1066,modest
1067,health care
1068,continuity on death
1069,rise
1070,unclear etiology
1071,accessibility
1072,non-diastolic
1073,accountable
1074,biventricular dysfunction
1075,divergent
1076,global attenuation
1077,western blot
1078,risk of death
1079,reliability
1080,society
1081,cardiac angiogenesis
1082,infarction-both
1083,evident
1084,outflow
1085,rheumatic fever
1086,mistargeting
1087,allopurinol
1088,health system
1089,qtv
1090,morphological
1091,documented
1092,histological
1093,protective peptides
1094,global longitudinal strain
1095,prostate
1096,adjustment
1097,observe
1098,mapping
1099,long-acting
1100,pigs
1101,changes in body
1102,angiotensin-receptor
1103,propensity score
1104,open-label
1105,decrement
1106,processed
1107,hospitalization
1108,preventing
1109,peak oxygen consumption
1110,core
1111,venoarterial dilation
1112,taxonomy
1113,responses
1114,aldosterone
1115,safety of spironolactone
1116,nonterminal epitopes
1117,il6
1118,controlling heart rate
1119,clinical practice
1120,study group
1121,stressors
1122,ameliorates
1123,61-77y
1124,explant
1125,reproducible
1126,treatable
1127,profoundly
1128,post-tac
1129,myocardial glycolysis
1130,potassium
1131,classified
1132,stand-alone
1133,actin
1134,office-based
1135,differential effect
1136,(tac)-induced
1137,nonprescribing
1138,metric
1139,blockers
1140,cost-effectiveness
1141,relating
1142,natriuretic peptide
1143,refractory right heart failure
1144,normalization
1145,sex-matched
1146,antitumor
1147,prescribing
1148,western blots
1149,interatrial shunting
1150,implantation
1151,brief
1152,dilatation diameter
1153,partial reduction
1154,acute coronary syndromes
1155,pre-pd
1156,recovery
1157,propensity-score
1158,uncontrolled
1159,systems level
1160,interquartile range
1161,two-vessel
1162,peripheral artery
1163,detecting
1164,ef
1165,readmission rate
1166,pre-crt
1167,noninvasive
1168,effect
1169,muscle strips
1170,pre-hct
1171,chf-inv
1172,cardiac dysfunction
1173,sought
1174,consumption rate
1175,hemodynamically
1176,osprey
1177,inappropriate
1178,beta-adrenergic
1179,lower von willebrand
1180,mena
1181,transcript
1182,exclusion criteria
1183,walk test
1184,wild-type
1185,measurements
1186,black race
1187,heart failure show
1188,policy
1189,mva
1190,tachypacing-induced
1191,identify
1192,echocardiography
1193,systolic heart failure
1194,admissions per
1195,fluid retention
1196,anastomosis
1197,gating
1198,adiponectin
1199,fee-for-service
1200,shunts
1201,circulatory assist device
1202,hfpef
1203,surgical conditions
1204,sci
1205,pump-exchange technique
1206,subproteome
1207,length of stay
1208,clinician
1209,at the point of care
1210,decades
1211,change in the case
1212,epinephrine
1213,nbdmard
1214,breathlessness
1215,medical treatment
1216,sacrificed
1217,pump
1218,hospital admissions
1219,electron microscopy
1220,event rate
1221,life expectancy
1222,vehicle
1223,aiming
1224,atypical
1225,myocardial angiogenesis
1226,technical advisors
1227,intubated
1228,preoperative renal dysfunction
1229,defense mechanism
1230,lower
1231,pef
1232,exhibited
1233,nontraumatic death
1234,tissue
1235,into mechanisms
1236,neonatal rat
1237,rcts
1238,adjusted hazard ratio
1239,with the lokomat® system
1240,preserves
1241,atrial
1242,/ sheet orientation
1243,life-sustaining
1244,index
1245,renin-angiotensin-aldosterone system
1246,normalized
1247,pacing
1248,unfolded
1249,translocation
1250,renin-angiotensin system blocker
1251,treating heart failure
1252,abnormal cardiac t2
1253,early-onset
1254,treatment for dilated cardiomyopathy
1255,cardiac-resynchronization
1256,health-related
1257,ed
1258,beat-to-beat
1259,age-dependent
1260,concern
1261,work remains
1262,hdl-bound
1263,hospital rankings
1264,adjunctive treatment
1265,phenylephrine-induced
1266,haemodynamic stress
1267,collagen
1268,lateral wall
1269,heart failure-related
1270,perturbed bone
1271,extrapolating
1272,postischemic heart failure
1273,underlies
1274,walking
1275,oxygen consumption
1276,die
1277,with interest
1278,nps
1279,systolic dysfunction
1280,mandate
1281,mouse
1282,uncommon
1283,electronic databases
1284,driven
1285,exchange malfunctioning
1286,better-than-usual
1287,agreement
1288,post-pd
1289,inotropes
1290,article
1291,vo2
1292,i2
1293,index admission
1294,hemocompatibility
1295,pharmacologic
1296,slows
1297,preventive measures
1298,participation
1299,internal diameter
1300,tolerance
1301,quality indicators
1302,atheromatous
1303,contention
1304,biomarkers
1305,reviewed
1306,score-matched
1307,additional risk
1308,post-transplant mortality
1309,dl
1310,quality of life
1311,breath-holding
1312,real-time
1313,reduction
1314,cumulative urine volume
1315,attributed
1316,recruited
1317,bypass
1318,aetiologies
1319,group
1320,right heart
1321,predicted values
1322,composite measure
1323,p=0·035
1324,functions
1325,contextual
1326,non-dnx
1327,walk
1328,discharges
1329,structure / function
1330,af
1331,self-care
1332,gender-matched
1333,children
1334,natriuretic peptides
1335,late-onset
1336,time to death
1337,large trials
1338,inpatient records
1339,fixed ring
1340,exercise-induced
1341,progenitor
1342,ec
1343,post-hct chf
1344,vo2max
1345,biomarker-guided
1346,ven
1347,atrial explant-derived
1348,aortic blood flow
1349,left bundle branch block
1350,shortens
1351,noninvasive assessments
1352,inverse
1353,timing
1354,advantage
1355,clinical trial
1356,left ventricular biopsies
1357,procedure-related
1358,well-treated
1359,hf-induced
1360,congestive
1361,major complications
1362,waist circumference
1363,pressure-overload
1364,activity
1365,acs
1366,group of patients
1367,practice
1368,pro-b-type
1369,center
1370,referred
1371,active
1372,non-cachectic
1373,hf
1374,hospital
1375,corporeal membrane oxygenation
1376,pyridostigmine
1377,act on the raas
1378,relies
1379,unstable
1380,slowness
1381,oht
1382,uncovered
1383,uneventful recovery
1384,20-week
1385,triggers
1386,administrative databases
1387,risk
1388,interrelated
1389,safety and efficacy
1390,myocardial ischaemia
1391,sampling
1392,clinical practice guidelines
1393,hospitalizations
1394,self-identified
1395,cardiac catheterization
1396,higher
1397,diuretic
1398,nonfunctional channels
1399,cardiomyopathy
1400,treating
1401,undergone
1402,9-s
1403,thrombotic
1404,perfusion
1405,inability
1406,filling flow
1407,attenuated
1408,warrants
1409,inactive
1410,treadmill testing
1411,interleukin
1412,intricately
1413,anti-inflammatory
1414,congenital abnormalities
1415,myocyte
1416,flow velocity
1417,pathways
1418,turbulence
1419,interview
1420,infarction-related
1421,downstream signaling
1422,hemodynamic alterations
1423,study
1424,diuretics
1425,albumin
1426,qt
1427,autopsy samples
1428,tricuspid
1429,derived
1430,halt
1431,cooperate
1432,rv
1433,large trial
1434,methylatropine
1435,total mortality
1436,primary end
1437,mediator
1438,readmissions
1439,administered
1440,qrs
1441,significant
1442,current treatment
1443,impact
1444,findings
1445,emean
1446,systolic
1447,ineligible
1448,potassium level
1449,regulation
1450,from the province of québec
1451,cardiac function
1452,stimulated
1453,hr
1454,undergoing renal dnx
1455,fiber
1456,vena cava
1457,exerted
1458,design
1459,hospital length
1460,blood-flow
1461,ischemic-hypertensive
1462,evidence
1463,ring annuloplasty
1464,cox
1465,patient safety
1466,sex
1467,avoidance
1468,regulatory
1469,ventricularly paced
1470,reverse remodeling
1471,cardiac
1472,pilot program
1473,monitor
1474,outpatients
1475,long-term survival
1476,blocker
1477,metoprolol succinate
1478,postmarketing trials
1479,adjuvant setting
1480,clinical care
1481,end-systolic elastance
1482,testing
1483,acute heart failure
1484,nonselective
1485,cutoff
1486,hospital for heart failure
1487,pilot
1488,adherence
1489,al. show
1490,nct00180271
1491,offset
1492,extubated
1493,aortic constriction
1494,non-lbbb
1495,splicing
1496,assessment
1497,antibodies
1498,rotor
1499,on mortality
1500,relative risk
1501,right ventricular function
1502,high mortality
1503,examine
1504,systolic function
1505,initiated
1506,interconnected
1507,renal artery stenosis
1508,acute care hospital for hf
1509,coordinate
1510,grip
1511,right ventricular pump
1512,sts
1513,contractile efficiency
1514,wk
1515,infarction
1516,hallmark
1517,signal transduction
1518,improved ventricular-arterial coupling
1519,hfpsi
1520,nervous systems
1521,acetylcholinesterase
1522,costs
1523,proportional hazard
1524,serum
1525,lying
1526,lower peak
1527,reporting
1528,bnp
1529,perioperative
1530,noted
1531,k=252
1532,american
1533,involved
1534,visits
1535,raloxifene
1536,cardiotoxicity
1537,clinical recommendations
1538,antitachycardia pacing
1539,life-threatening
1540,differentially
1541,composite end
1542,care outcomes
1543,time frame
1544,associated
1545,restriction
1546,antiplatelet drugs
1547,abolished
1548,end-of-life
1549,exercise training
1550,striking
1551,pacemakers
1552,animal
1553,carries
1554,full-length
1555,intention-to-treat
1556,cardiomyocytes
1557,pathophysiology
1558,cardiac index
1559,immunoreactive
1560,middle-aged
1561,conclusion and relevance
1562,biological
1563,hhf
1564,examining
1565,arthritis
1566,adhesion
1567,growth
1568,hfvt(+)
1569,402.x1
1570,combined treatment
1571,median
1572,cvd
1573,extracorporeal
1574,therapeutic treatments
1575,independent
1576,embedded
1577,biomedical treatment
1578,changes in energy metabolism
1579,organisation
1580,unfamiliar
1581,conferred
1582,coronary artery
1583,heart transplantation
1584,bets
1585,pharmaceutically
1586,follow-up
1587,wt
1588,fm
1589,device
1590,growth factor
1591,therapy
1592,prediction model
1593,et
1594,medical management
1595,valvular
1596,end-systole
1597,body mass
1598,monitoring
1599,real world
1600,postcontrast
1601,non-aas
1602,inpatient medical conditions
1603,transient
1604,difference-in-differences
1605,non-fatal stroke
1606,follow-up echocardiograms
1607,'d
1608,electrocardiographers
1609,angina
1610,standard care
1611,cardiology
1612,attrition
1613,non-survivors
1614,delayed
1615,transition markers
1616,fatty acids
1617,economic savings
1618,pro-brain natriuretic peptide
1619,end-diastolic
1620,higher-than-expected
1621,dialysis
1622,atrial pacing
1623,modifiable risk
1624,unaltered
1625,evaluating
1626,combined end
1627,methods
1628,ckd
1629,ans
1630,cardiovascular risk
1631,relationship
1632,public health
1633,chf-dnx
1634,clinical evaluation
1635,differences in longitudinal performance
1636,multiorgan failure
1637,covariates
1638,identification
1639,stenotic
1640,distinguish
1641,combining
1642,guiding
1643,independently
1644,ring
1645,hipsc-cms
1646,alternatives
1647,right ventricular
1648,functioning
1649,induced recovery
1650,cardiovascular death
1651,left ventricular hypertrophy
1652,nanomolar
1653,rwt
1654,self-reported
1655,general
1656,glomerular filtration rate
1657,high-sensitivity
1658,vehicle-treated
1659,pacing-induced
1660,pacemaker
1661,markers
1662,study-drug
1663,purpose of review
1664,acp
1665,total adiponectin
1666,data sources
1667,objectives
1668,ventricular dysfunction
1669,reduced mortality risk
1670,obesity
1671,north america
1672,diet score
1673,poor prognosis
1674,sst2
1675,education
1676,moderate-quality
1677,altering
1678,inpatient admissions
1679,under the curve
1680,tachycardia-induced
1681,warranted
1682,dimension index
1683,expansion
1684,effective
1685,dash
1686,transseptal catheterisation
1687,insufficiency
1688,thorough medical
1689,paediatric
1690,decreases in septum
1691,upr
1692,titrated
1693,controls
1694,hospitalization for heart failure
1695,medicare fee-for-service
1696,o2 per kilogram
1697,stable
1698,unsuccessful
1699,2+)-pump
1700,repeat procedures
1701,collateral growth
1702,integrated
1703,projecting
1704,concentrations
1705,noncoding
1706,energy metabolism
1707,statistical
1708,seven
1709,samples
1710,change in c-index
1711,awful
1712,diastolic function
1713,monitoring devices
1714,discharge
1715,endothelial dysfunction
1716,heart failure hospitalization
1717,nonmitochondrial
1718,aha
1719,single-payer
1720,quality-of-life
1721,etiology
1722,defined
1723,load-corrected
1724,whites
1725,trial of nordic walking
1726,venous thromboembolic
1727,rheumatoid arthritis
1728,statistical parameters
1729,transmitral flow
1730,key
1731,after ring annuloplasty
1732,reperfusion therapy
1733,use
1734,peptides
1735,non-ischemic
1736,test-retest
1737,protection
1738,inoperable
1739,success rate
1740,reports
1741,10-eo-cfu
1742,independent risk factor
1743,new therapeutic
1744,continuity equation
1745,demographic
1746,assist devices
1747,investigating
1748,lifesaving drugs
1749,summary
1750,pvf
1751,coronary artery disease
1752,consumes
1753,common
1754,claims
1755,lv
1756,baroreflex
1757,individual
1758,work rate
1759,quality measures
1760,individuals
1761,reactivation
1762,across-the-board
1763,absorption function
1764,amyloidotic
1765,tonometry
1766,initial safety
1767,channel-dependent
1768,phosphocreatine
1769,nursing
1770,change in 30-day
1771,single-centre
1772,ees
1773,well-being
1774,diastolic failure
1775,readmission quality
1776,twenty-seven
1777,reveal
1778,pronounced
1779,bet
1780,narrow
1781,measurement systems
1782,aerobic
1783,mo
1784,tuscany
1785,glucose transporter
1786,coprimary
1787,peak oxygen
1788,nonfatal
1789,criterion standard
1790,incubated
1791,sequence-specific
1792,subspecialty
1793,network
1794,hospital for worsening heart failure
1795,association of cognitive impairment
1796,income per capita
1797,resting hr
1798,decompensation
1799,delay
1800,p70s6k-ser
1801,sustainability
1802,over-represented
1803,myocardial t1
1804,decrease
1805,muscle-wasting syndrome
1806,acr
1807,inclusion criteria
1808,kidney index
1809,combined care
1810,american college of physicians
1811,normal albumin
1812,progenitor cells
1813,uk
1814,peripheral muscles
1815,evidence-based
1816,admission
1817,brain natriuretic peptide
1818,levitated
1819,single-center
1820,deficit index
1821,cardiomyocyte
1822,treat
1823,recurrent
1824,double-blind
1825,strokes
1826,imaging
1827,decrease mortality
1828,phosphorylation
1829,kappa
1830,preoperative
1831,latter
1832,association of hypoalbuminemia
1833,combine
1834,gadolinium-chelate
1835,optimal therapy
1836,with.estimates
1837,global changes
1838,no toxicity
1839,anthracyclines
1840,mass index
1841,humans
1842,actrn12610001087044
1843,derive
1844,waves
1845,endothelial-protective
1846,recruitment
1847,edge-to-edge anastomosis
1848,immunoprecipitation
1849,standard error
1850,health
1851,contact
1852,kidney failure
1853,excluded
1854,health care system
1855,data show
1856,bradyarrhythmias
1857,nonfailing
1858,transition
1859,barriers
1860,on cardiac function
1861,aggravate
1862,detection
1863,evaluation
1864,shunt implantation
1865,moderate heart failure
1866,review protocol
1867,receptors
1868,acetyl-lysine
1869,treatment strategies
1870,engage
1871,hospitalized heart failure
1872,referrals
1873,30-day
1874,acute hospital
1875,continuous wave
1876,unloads
1877,demonstrate
1878,over
1879,enrollment
1880,transgenic
1881,standard therapy
1882,system of zebrafish
1883,debate
1884,msec
1885,decision-support
1886,decreased
1887,main outcome measure
1888,downstream signalling
1889,clinical tool
1890,etidronate
1891,hypertension
1892,currents
1893,diastolic
1894,nbdmards
1895,canine
1896,periprocedural
1897,high-dose
1898,underlie
1899,elderly
1900,content-driven
1901,aldosterone blockade
1902,reversed
1903,left ventricular tissue
1904,anthracycline-related
1905,general anaesthesia
1906,severe
1907,cytochrome c
1908,race / ethnicity
1909,caring
1910,myocardial diastolic dysfunction
1911,central glycosylated
1912,analyzed
1913,change
1914,ejection
1915,receptor blocker
1916,measures
1917,transduction pathways
1918,cardiac chromatin
1919,propensity
1920,rheumatic
1921,deactivation
1922,adopting
1923,contribute
1924,systemic vascular resistance
1925,inotrope-dependent
1926,resolution
1927,oxygenation
1928,c-kit
1929,unfit
1930,control therapy
1931,evolution
1932,conflicting
1933,resistance
1934,colony-forming units
1935,free mass
1936,adenine
1937,postmenopausal
1938,intubation rates
1939,multicenter
1940,conclusions and relevance
1941,25mg
1942,nodularity
1943,inverse association
1944,biopsies
1945,transcriptional
1946,mechanical cardiac
1947,evaluated
1948,regression analysis
1949,atrial myxoma
1950,systolic blood pressure
1951,evaluate
1952,activities
1953,oversewing
1954,diet scores
1955,per os
1956,discrepancy
1957,kccq
1958,fatigue
1959,or
1960,research requirements
1961,reduced cardiac fibrosis
1962,coefficients
1963,re-hospitalization
1964,hospitalized
1965,administrative health
1966,from the ncdr pinnacle program
1967,free wall
1968,diminishing
1969,legal majority
1970,continuous-flow
1971,uncontrolled hypertension
1972,amyloidosis
1973,debilitating
1974,first-in-class inhibitor
1975,disseminate
1976,overview
1977,sodium restriction
1978,hypertrophy
1979,reduction of sympathetic activity
1980,refuse
1981,restricted
1982,single-arm
1983,high-strength
1984,define
1985,cardiac cachexia
1986,body
1987,introduced
1988,subgroup
1989,stroke
1990,no
1991,pulse sequence
1992,blood flow velocity
1993,ascertain
1994,tactics
1995,conclusions
1996,enhancing medical management
1997,atrial area
1998,matched-pairs
1999,confounding
2000,observational studies
2001,composite endpoint
2002,senescence
2003,quality improvement
2004,closure
2005,percutaneous
2006,atrial pressure
2007,main outcome measures
2008,biomarker
2009,emission tomography
2010,plasticity
2011,allogeneic
2012,irs1
2013,outweigh
2014,subset
2015,overexpressing
2016,pro-brain
2017,medical support
2018,deciles
2019,washout
2020,likelihood ratio
2021,with
2022,differences
2023,nondiabetic
2024,prodrug
2025,all-cause
2026,sacubiltril
2027,noncardiac
2028,failing hearts
2029,redesigned
2030,reducing
2031,retrieved
2032,pathway analysis
2033,health service
2034,rat
2035,echocardiographic score
2036,intermediate care
2037,counterparts
2038,lv dysfunction
2039,intermuscular fat ratio
2040,cohorts
2041,circulating
2042,mortality rate
2043,budget
2044,joint effect
2045,demonstrated
2046,devices
2047,serious harms
2048,divided
2049,newly
2050,nonadherence
2051,guideline-recommended
2052,decreasing
2053,continuous flow
2054,haplotype
2055,atrioventricular delay
2056,logistic regression
2057,time interval
2058,risk-adjusted
2059,anthracycline
2060,camp-dependent
2061,hospital-to-home
2062,antiplatelet
2063,congenital
2064,cardiac arrest
2065,dyspnea
2066,limits
2067,longitudinal analysis
2068,post-transplant
2069,major
2070,treatment for heart failure
2071,decile
2072,preclude
2073,lad
2074,associations
2075,heavy chain
2076,suppression
2077,black ethnicity
2078,open surgery
2079,dialysis-dependent
2080,respiration
2081,borderline
2082,age group
2083,nonsurvivors
2084,mrnas
2085,factorial trial
2086,acceptable
2087,crt-d
2088,going
2089,lbbb
2090,outpatient settings
2091,dithiothreitol
2092,hf-ref
2093,tethering
2094,transfusion strategy
2095,congenital heart
2096,remarkable
2097,reveals
2098,equally
2099,data extraction
2100,caspase-3
2101,noncardiovascular
2102,mediating
2103,old
2104,third trial
2105,air
2106,co-ordinated
2107,resonance imaging
2108,nosignificant
2109,resting hemodynamics
2110,hospital admission
2111,median age
2112,flow-mediated
2113,cardiovascular reserve
2114,published
2115,survivors
2116,vagal
2117,bisoprolol
2118,ser83
2119,v.6.2
2120,assisted
2121,thromboembolic
2122,ref
2123,defibrillator-only
2124,participating clinics
2125,on units accustomed
2126,human hf
2127,hepatic function
2128,left ventricular systolic
2129,aim
2130,sufficient
2131,receptor
2132,myocytes
2133,managing
2134,training
2135,enrolled
2136,confidence
2137,per cent
2138,observed
2139,limbs
2140,gait
2141,coding
2142,hfvt(-)
2143,atrial tachyarrhythmias
2144,risk of stroke
2145,beat
2146,contractile
2147,controlling
2148,showed
2149,work
2150,characterized
2151,left pulmonary artery
2152,rhythm
2153,study design
2154,nervous system
2155,risk reduction
2156,pathology
2157,explanted
2158,exacerbation
2159,mid lad
2160,case-control
2161,reducing mortality
2162,degenerative
2163,wall
2164,post-translational
2165,positive
2166,postoperative
2167,double mutant
2168,transiently
2169,global left ventricular
2170,feasibility
2171,cinahl
2172,extending
2173,refractory cardiogenic shock
2174,lean zsf1
2175,supporting
2176,subvalvular
2177,rs
2178,ami
2179,diuretic refractory
2180,performed
2181,new antiarrhythmic drugs
2182,sodium-restricted
2183,atrium
2184,quintiles
2185,equation
2186,data in latin america
2187,cyclase
2188,composite end-point
2189,circulatory failure
2190,chromatin
2191,mutually exclusive
2192,gait therapy
2193,activation
2194,subgroups
2195,undertaken
2196,nephrectomy
2197,rrna
2198,doxorubicin-induced
2199,working hearts
2200,catabolic / anabolic imbalance
2201,respect
2202,moderate-intensity
2203,left ventricular base
2204,not
2205,cornerstone
2206,eplerenone
2207,tracking
2208,above
2209,amelioration
2210,influences
2211,disappointments
2212,albeit
2213,clinical setting
2214,delineated
2215,428.xx
2216,hospital discharge
2217,vitro
2218,mir-25
2219,occurred
2220,health benefits
2221,unsuitable
2222,crf
2223,icd-hf
2224,characteristics yielded hazard ratios
2225,training protocol
2226,copd
2227,economic
2228,clinical
2229,intake
2230,assays
2231,urea nitrogen
2232,grading system
2233,codes
2234,classification of diseases
2235,common consensus
2236,tachycardic
2237,multicenter trial
2238,myocardial oxygen consumption
2239,preliminary study
2240,left
2241,placebo
2242,interplay
2243,unchanged
2244,increased
2245,moderate reduction
2246,collinearity
2247,muscles
2248,resting
2249,psychometric
2250,lower btes
2251,extensive
2252,trpm7
2253,medical
2254,erc
2255,anemic
2256,follow
2257,acetyltransferases
2258,white
2259,flow-mediated dilatation
2260,dd
2261,end-diastolic pressure
2262,combinations
2263,agonist
2264,blood flow
2265,cause of mortality
2266,muscular
2267,brd4
2268,myocardial perfusion
2269,avoids
2270,nitroxyl
2271,central venous
2272,chest
2273,breast cancer
2274,evolving
2275,office
2276,replacement
2277,leading
2278,quantitative proteomics
2279,adverse
2280,extracellular matrix
2281,angiogenesis
2282,resection
2283,thirty-seven hospitals
2284,mlhf
2285,expression
2286,age-matched
2287,open
2288,non-sudden
2289,pulse
2290,right
2291,multiple myeloma
2292,postoperative normalization
2293,referral centre
2294,outcomes and measures
2295,in the united states
2296,cv
2297,shortening
2298,venous thromboembolism
2299,maladaptive
2300,mechanism of cardioprotection
2301,inhibitory
2302,cross-sectional
2303,non-randomized
2304,amenable
2305,diuretic therapy
2306,low-frequency
2307,criteria
2308,uncertain
2309,placebo group
2310,hyperlipidaemia
2311,/ flutter
2312,clinical effects
2313,displaced
2314,i.p.
2315,due
2316,use of bisoprolol
2317,attenuation
2318,angiotensin-aldosterone
2319,systolic ventricular function
2320,exchange
2321,structural heart
2322,statistical standards
2323,multimarker-based strategy
2324,beta-blocker
2325,despite
2326,brachial
2327,duplicate
2328,structure
2329,participating nurses
2330,midpapillary
2331,measurement value
2332,change in cystatin c
2333,morphogenetic
2334,open chest model
2335,myocardium
2336,develop
2337,parallel-group
2338,safety measures
2339,independent association
2340,subdomains
2341,ascertained
2342,systemic hypertension
2343,advanced heart failure
2344,hypertensive
2345,circulatory arrest
2346,arm cuff
2347,hospitalisation
2348,dogs
2349,separately
2350,arrhythmia
2351,analyses
2352,individualized assessment
2353,meeting
2354,left ventricular filling
2355,detected
2356,suboptimal
2357,pure epicatechin
2358,regulated
2359,anthracycline-treated
2360,local cardiology services
2361,age - and gender-matched
2362,resulting
2363,expressed
2364,clinical response
2365,tomographic angiography
2366,acetylcholinesterase inhibition
2367,motions
2368,afterload
2369,echocardiographic
2370,functional
2371,treatment and clinical course
2372,underwent
2373,body mass index
2374,body composition
2375,contemporary
2376,inroads
2377,high-fat diet
2378,commissioning
2379,uninephrectomy
2380,4-fold
2381,equitable
2382,hdl particles
2383,hearts
2384,displaces
2385,extensively
2386,pressure-overload-induced
2387,drug administration
2388,beyond the cardiovascular system
2389,calls
2390,central blood pressure
2391,identified
2392,ip
2393,postoperative survival
2394,optimize
2395,clinical status
2396,cardiac resynchronization therapy
2397,mri
2398,adenylyl cyclase
2399,vs. pasp
2400,acute myocardial infarction
2401,guideline-directed
2402,signaling
2403,clinical outcome
2404,standard echocardiographic measurements
2405,risk of heart failure
2406,histologic
2407,operation
2408,unanchors
2409,medical center
2410,standard cardiac rehabilitation
2411,elevations
2412,euthanization
2413,peritoneal dialysis
2414,preoperative serum albumin
2415,adult mouse
2416,pharmaceuticals
2417,etiologies
2418,pay-for-performance
2419,infusions
2420,logistic analysis
2421,presenting
2422,bromodomain
2423,atherosclerosis
2424,rheumatoid
2425,interventions
2426,medical therapy
2427,event-free
2428,iron homeostasis
2429,confounded
2430,modestly
2431,driveline
2432,accounting
2433,the
2434,risk of incident
2435,age-by-lvef
2436,hscrp
2437,carcinoma
2438,clinical circumstances
2439,schfi
2440,fluid
2441,first-in-man
2442,postoperatively
2443,transcription
2444,decade
2445,therapeutic strategy
2446,instability
2447,double-blind trial
2448,cytotoxic
2449,thus
2450,end-systolic
2451,counterbalance
2452,frailty
2453,aging
2454,pathogenesis
2455,raloxifene-treated
2456,data analysis
2457,unreliable
2458,renin
2459,emotional stress
2460,beneficial effect
2461,t1
2462,pulse-wave velocity
2463,expressing
2464,compelling
2465,bolus
2466,left heart twist
2467,beta blockers
2468,duration
2469,risk for stroke
2470,unfavorable
2471,infrequent
2472,extracorporeal membrane oxygenation
2473,cytoskeletal
2474,therapeutic
2475,leads
2476,enhancing
2477,diminished
2478,normal samples
2479,connected
2480,external
2481,undergoing
2482,renin-angiotensin-aldosterone
2483,prescribed
2484,cytoskeleton
2485,serious
2486,development of cardiac hypertrophy
2487,p70s6k
2488,tricuspid annular plane systolic excursion
2489,conducting
2490,explants
2491,platelet-activating factor
2492,identifying
2493,attenuating
2494,peripheral vascular disease
2495,underwent device
2496,10-cell
2497,ecct
2498,heart dilatation
2499,characteristics
2500,connection
2501,human
2502,endpoints
2503,spectrometric analysis
2504,single-institution
2505,resynthesis
2506,tta
2507,denotes
2508,elateral
2509,deacetylases
2510,mrna
2511,neurotransmission
2512,allocation ratio
2513,prevention
2514,balance
2515,human-to-machine
2516,right coronary artery
2517,abstract
2518,clin
2519,at the apex
2520,β-ar
2521,well-recognised
2522,responsive
2523,8-fluo-camp
2524,activating
2525,subtle changes
2526,bleeding
2527,health insurance
2528,abnormalities
2529,co-morbidity
2530,primary endpoint
2531,assay
2532,uptitration
2533,adenoviral vector
2534,uptitrations
2535,twist
2536,readmission
2537,highest
2538,antiplatelet agents
2539,myofibrillar
2540,support
2541,heart transplant
2542,expansion protocols
2543,from the heart function clinic
2544,objective
2545,assist device
2546,contracting ventricles
2547,professionals
2548,weight loss
2549,general populations
2550,abdominal
2551,frail
2552,power index
2553,bpm
2554,adjunctive
2555,anthracycline-containing
2556,weak
2557,integrates
2558,developed
2559,importance
2560,inpatient
2561,jehovah
2562,catabolism
2563,blood
2564,further investigation
2565,confidence intervals
2566,methods and results
2567,left-hand
2568,left ventricular ejection
2569,cellular plasticity
2570,extend
2571,acetyltransferase
2572,cogeneration
2573,enhancement imaging
2574,myocyte-specific
2575,left ventricular ejection fraction
2576,flow velocities
2577,proangiogenic
2578,practices
2579,myocarditis
2580,btes
2581,conclusion
2582,ea
2583,subpulmonary ventricle
2584,biventricular
2585,differential
2586,kidney
2587,improves
2588,report
2589,medicare
2590,cumulative hazard
2591,drive
2592,rats
2593,standardized nursing
2594,hand
2595,beneficial effects
2596,activate
2597,hm
2598,superfamily
2599,financial incentives
2600,crt
2601,accompanied
2602,resulted
2603,stress
2604,transfusion
2605,2-fold
2606,demographic changes
2607,mixed
2608,study period
2609,expenditure
2610,nursing facilities
2611,haemodynamic assessment
2612,ameliorated
2613,congestive heart failure
2614,composite hf index
2615,contractility
2616,extracellular flux analyzer
2617,low-dose
2618,tested
2619,overweight
2620,enriched
2621,time-limited
2622,myocardial tissues
2623,accounted
2624,trigger
2625,role
2626,stretch
2627,explant-derived
2628,imaging techniques
2629,breathing control
2630,absolute improvements
2631,transoesophageal
2632,elevation
2633,imbalance
2634,ml
2635,hospitalisations
2636,deposition
2637,reprogramming
2638,dipeptidyl
2639,biopsy
2640,exponent
2641,regression line
2642,physiology
2643,noncardiologist
2644,endoplasmic reticulum
2645,peripheral edema
2646,correlated
2647,fibrillation
2648,length-force
2649,show
2650,history and clinical findings
2651,multisite
2652,peak respiratory quotient
2653,measuring
2654,s'septal
2655,left ventricular mechanics
2656,defence
2657,changes
2658,spent
2659,design and patients
2660,off-pump
2661,health care systems
2662,prolapse
2663,eh
2664,same
2665,receiver operating
2666,post
2667,nontrastuzumab
2668,shorter
2669,dissemination
2670,sternal sparing
2671,parasympathetic
2672,antihyperglycemic agents
2673,emotional
2674,compensated
2675,conventional surgery
2676,hyperkalemia
2677,mixed-methods
2678,beats
2679,intervention
2680,skilled
2681,lcx
2682,muscle
2683,acute kidney
2684,loading
2685,unplanned
2686,bodies
2687,clinical characteristics
2688,serum sodium
2689,harms
2690,counteracted
2691,precapillary
2692,nationally
2693,demonstrating
2694,led
2695,atrial fibrillation
2696,leg
2697,skinfold thickness
2698,ie
2699,regulates
2700,myosin
2701,outcomes trial
2702,anthracycline-induced
2703,bypass grafting
2704,controlled
2705,pathological hypertrophy
2706,cost-effective
2707,turned on
2708,per se
2709,advanced
2710,trichrome
2711,saf
2712,ejection fractions
2713,age - and sex-adjusted risk
2714,flow reserve measurements
2715,system inhibitors
2716,aged
2717,physiologic
2718,statistically
2719,inhospital mortality
2720,intubations
2721,untranslated
2722,sepsis
2723,untreated
2724,primary culprit
2725,dxa
2726,decreases
2727,bioprosthetic
2728,bhlh
2729,right ventricular-pulmonary
2730,reclassification
2731,6-mwt
2732,trastuzumab-related
2733,basal rotations
2734,first-ever
2735,methodology
2736,et al
2737,proportional hazards
2738,neglected
2739,curves
2740,mortality risk
2741,inconsistent
2742,myocardial infarction
2743,acute coronary syndrome
2744,elucidate mechanisms
2745,strain
2746,childhood malignant
2747,lusitropic
2748,rs10927887
2749,erk1
2750,consistency
2751,global proteomics
2752,nitric oxide donors
2753,creatine kinase
2754,prone
2755,bound
2756,placebo-controlled
2757,embryonic
2758,transmitral
2759,sternotomy
2760,cumulative
2761,postsystolic
2762,subjected
2763,nondiabetes risk
2764,differential analysis
2765,observational
2766,drs
2767,value=0.631
2768,unilateral
2769,geometry
2770,hgb
2771,re-activating
2772,ages
2773,regional circumferential strain
2774,leaflet
2775,prescriptive
2776,pump failure
2777,right pulmonary artery
2778,pairwise
2779,analysis
2780,value=0.027
2781,auscultation
2782,from
2783,body weight
2784,exposed
2785,reflective
2786,end stage
2787,passive / stiffness
2788,carbohydrates
2789,change in
2790,lead
2791,systematic review
2792,management
2793,people
2794,sdqt
2795,low-quality
2796,home
2797,lower mortality
2798,breathing
2799,interagency registry
2800,lean mass index
2801,behavioural-change
2802,circulation
2803,sympathovagal balance
2804,thereby
2805,stored
2806,meq
2807,relates
2808,lower lvef
2809,writer
2810,double-knockout
